After years of excluding anti-obesity medications from Part D coverage, Medicare is launching a landmark bridge program in July 2026 that will cover GLP-1 medications for eligible beneficiaries. This guide covers everything we know about the program, how to prepare, and what it means for Medicare recipients seeking weight management treatment.
Background: Why Medicare Excluded Weight Loss Drugs
Medicare Part D has historically excluded coverage for medications used solely for weight loss or cosmetic purposes. This exclusion was established by statute in 2003 when Part D was created. Despite the FDA approving multiple anti-obesity medications and the recognition of obesity as a disease, Medicare maintained this exclusion until legislative action in late 2025 created the bridge program.
The Bridge Program Structure
The Medicare GLP-1 Bridge Program is designed as a transitional coverage mechanism. It is not permanent Medicare Part D coverage but rather a three-year pilot program that will provide coverage for FDA-approved GLP-1 medications used for weight management. The program launches July 1, 2026, and is currently authorized through June 30, 2029.
Eligibility Requirements
Based on the published program guidelines, eligibility requires:
- Active Medicare Part D enrollment
- Body mass index (BMI) of 35 or higher
- At least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease)
- Documentation of at least one prior weight management attempt (diet, exercise program, or behavioral intervention)
- Prescribing physician must be enrolled in Medicare and participate in the program
Covered Medications
The bridge program covers FDA-approved GLP-1 receptor agonists and dual GIP/GLP-1 agonists indicated for weight management. As of the program launch, this includes Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). It does not cover compounded medications or off-label use of diabetes-approved formulations like Ozempic or Mounjaro.
Expected Cost Sharing
CMS has not yet finalized the cost-sharing structure for the bridge program. Industry analysts expect a copay structure similar to Medicare Part D specialty tier medications, which would put monthly out-of-pocket costs in the range of $50 to $150 for most beneficiaries. Beneficiaries who qualify for Low Income Subsidy (Extra Help) may have lower or no copays.
How to Prepare
If you are a Medicare beneficiary interested in the bridge program, start preparing now:
- Confirm your Part D enrollment is active and your plan will participate in the bridge program
- Schedule an appointment with your physician to discuss eligibility and document your BMI and comorbidities
- Gather documentation of any prior weight management attempts
- Request baseline lab work including metabolic panel, A1C, and lipid panel
- Research participating prescribers in your area
Impact on the GLP-1 Market
The Medicare bridge program is expected to significantly increase demand for GLP-1 medications. Medicare covers approximately 65 million Americans, and obesity prevalence in the Medicare population exceeds 40%. Even with restrictive eligibility criteria, millions of beneficiaries may qualify. This increased demand could impact supply and pricing dynamics across the entire market.
For current information on GLP-1 medication availability, pricing, and provider reviews, a comprehensive comparison of 29+ providers is available at GLP-1 Watchdog.
Looking Ahead
The bridge program is widely viewed as a stepping stone toward permanent Medicare coverage for anti-obesity medications. If the program demonstrates positive health outcomes and cost savings, which most analysts expect, it will build the case for legislative action to remove the Part D anti-obesity medication exclusion entirely. We will continue to monitor developments and update this guide as new information becomes available.